An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells
Ivana Campia, Ilaria Buondonno, Barbara Castella, Barbara Rolando, Joanna Kopecka, Elena Gazzano, Dario Ghigo, Chiara Riganti, Ivana Campia, Ilaria Buondonno, Barbara Castella, Barbara Rolando, Joanna Kopecka, Elena Gazzano, Dario Ghigo, Chiara Riganti
Abstract
Background: Multidrug resistant cancer cells are hard to eradicate for the inefficacy of conventional anticancer drugs. Besides escaping the cytotoxic effects of chemotherapy, they also bypass the pro-immunogenic effects induced by anticancer drugs: indeed they are not well recognized by host dendritic cells and do not elicit a durable anti-tumor immunity. It has not yet been investigated whether multidrug resistant cells have a different ability to induce immunosuppression than chemosensitive ones. We addressed this issue in human and murine chemosensitive and multidrug resistant cancer cells.
Results: We found that the activity and expression of indoleamine 2,3-dioxygenase 1 (IDO1), which catalyzes the conversion of tryptophan into the immunosuppressive metabolite kynurenine, was higher in all the multidrug resistant cells analyzed and that IDO1 inhibition reduced the growth of drug-resistant tumors in immunocompetent animals. In chemoresistant cells the basal activity of JAK1/STAT1 and JAK1/STAT3 signaling was higher, the STAT3 inhibitor PIAS3 was down-regulated, and the autocrine production of STAT3-target and IDO1-inducers cytokines IL-6, IL-4, IL-1β, IL-13, TNF-α and CD40L, was increased. The disruption of the JAK/STAT signaling lowered the IDO1 activity and reversed the kynurenine-induced pro-immunosuppressive effects, as revealed by the restored proliferation of T-lymphocytes in STAT-silenced chemoresistant cells.
Conclusions: Our work shows that multidrug resistant cells have a stronger immunosuppressive attitude than chemosensitive cells, due to the constitutive activation of the JAK/STAT/IDO1 axis, thus resulting chemo- and immune-evasive. Disrupting this axis may significantly improve the efficacy of chemo-immunotherapy protocols against resistant tumors.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Gottesman MM, Fojo T, Bates SE (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2(1): 48–58.
- Agarwal S, Sane R, Oberoi R, Ohlfest JR, Elmquist WF (2011) Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med 13: e17 10.1017/S1462399411001888
- Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13(1): 54–61.
- De Boo S, Kopecka J, Brusa D, Gazzano E, Matera L, Ghigo D, et al. (2009) iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells. Mol Cancer 8: e108.
- Kopecka J, Campia I, Brusa D, Doublier S, Matera L, Ghigo D, et al. (2011) Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells. J Cell Mol Med 15(7): 1492–1504. 10.1111/j.1582-4934.2010.01137.x
- Riganti C, Castella B, Kopecka J, Campia I, Coscia M, Pescarmona G, et al. (2013) Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells. PLoS One 8(4): e60975 10.1371/journal.pone.0060975
- Burkholder B, Huang RY, Burgess R, Luo S, Jones VS, Zhang W, et al. (2014) Tumor-induced perturbations of cytokines and immune cell networks. Biochim Biophys Acta 1845(2): 182–201. 10.1016/j.bbcan.2014.01.004
- Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, et al. (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478(7368): 197–203. 10.1038/nature10491
- Prendergast GC (2011) Cancer: Why tumors eat tryptophan. Nature 478(7368): 192–194. 10.1038/478192a
- Ozaki Y, Edelstein MP, Duch DS (1988) Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon gamma. Proc Natl Acad Sci USA 85(4): 1242–1246.
- Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC (2007) Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 67(15): 7082–7087.
- Thomas SR, Terentis AC, Cai H, Takikawa O, Levina A, Lay PA, et al. (2007) Post-translational regulation of human indoleamine 2,3-dioxygenase activity by nitric oxide. J Biol Chem 282(33): 23778–23787.
- Krausse-Opatz B, Wittkop U, Gutzki FM, Schmidt C, Jürgens-Saathoff B, Meier S, et al. (2009) Free iron ions decrease indoleamine 2,3-dioxygenase expression and reduce IFNgamma-induced inhibition of Chlamydia trachomatis infection. Microb Pathog 46(6): 289–297. 10.1016/j.micpath.2009.03.001
- Lu B, Finn OJ (2008) T-cell death and cancer immune tolerance. Cell Death Differ 15(1): 70–79.
- Harden JL, Egilmez NK (2012) Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity. Immunol Invest 41(6–7): 738–764. 10.3109/08820139.2012.692418
- Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, et al. (2006) Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 213: 131–145.
- Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, et al. (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9(10): 1269–1274.
- Suzuki Y, Suda T, Furuhashi K, Suzuki M, Fujie M, Hahimoto D, et al. (2010) Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer 67(3): 361–365. 10.1016/j.lungcan.2009.05.001
- Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y, et al. (2005) Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 11(16): 6030–6039.
- Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, et al. (2006) Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumour-infiltrating T cells. Clin Cancer Res 12(4): 1144–1151.
- Ino K, Tanizaki Y, Kobayashi A, Toujima S, Mabuchi Y, Minami S (2012) Role of the Immune Tolerance-Inducing Molecule Indoleamine 2,3-Dioxygenase in Gynecologic Cancers. J Cancer Sci Ther 13: e004.
- Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, et al. (2012) IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov 2(8): 722–735. 10.1158/-12-0014
- Cacciotti P, Libener R, Betta P, Martini F, Porta C, Procopio A, et al. (2001) SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma. Proc Natl Acad Sci USA 98(21):12032–12037.
- Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, et al. (2007) Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 67(2): 792–801.
- Zhang X, He Y, Ding M (2009) Simultaneous determination of tryptophan and kynurenine in plasma samples of children patients with Kawasaki disease by high-performance liquid chromatography with programmed wavelength ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 877(16–17):1678–1682.
- Lee B, French K, Zhuang Y, Smith C (2003) Development of a syngeneic in vivo tumor model and its use in evaluating a novel p-glycoprotein modulator, pgp-4008. Oncol Res 14(1): 49–60.
- Banerjee T, Duhadaway JB, Gaspari P, Sutanto-Ward E, Munn DH, Mellor AL, et al. (2008) A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene 27(20): 2851–2857.
- Gelsomino G, Corsetto PA, Campia I, Montorfano G, Kopecka J, Castella B, et al. (2013) Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition. Mol Cancer 12: e137.
- Riganti C, Costamagna C, Doublier S, Miraglia E, Polimeni M, Bosia A, et al. (2008) The NADPH oxidase inhibitor apocynin induces nitric oxide synthesis via oxidative stress. Toxicol Appl Pharmacol 228(3): 277–285. 10.1016/j.taap.2007.12.013
- Qian F, Villella J, Wallace PK, Mhawech-Fauceglia P, Tario JD Jr, Andrews C, et al. (2009) Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer. Cancer Res 69 (13): 5498–5504. 10.1158/0008-5472.CAN-08-2106
- Gough DJ, Levy DE, Johnstone RW, Clarke CJ (2008) IFNgamma signaling-does it mean JAK-STAT? Cytokine Growth Factor Rev 19(5–6): 383–394.
- Orabona C, Grohmann U (2011) Indoleamine 2, 3-dioxygenase and regulatory function: tryptophan starvation and beyond. Methods Mol Biol 677: 269–280. 10.1007/978-1-60761-869-0_19
- Sun Y, Chin YE, Weisiger E, Malter C, Tawara I, Toubai T, et al. (2009) Cutting edge: Negative regulation of dendritic cells through acetylation of the non histone protein STAT-3. J Immunol 182(10): 5899–5903. 10.4049/jimmunol.0804388
- Litzenburger UM, Opitz CA, Sahm F, Rauschenbach KJ, Trump S, Winter M, et al. (2014) Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget 5(4): 1038–1051.
- Yadav MC, Burudi EM, Alirezaei M, Flynn CC, Watry DD, Lanigan CM, et al. (2007) IFN-gamma-induced IDO and WRS expression in microglia is differentially regulated by IL-4. Glia 55(13): 1385–1396.
- Zunszain PA, Anacker C, Cattaneo A, Choudhury S, Musaelyan K, Myint AM, et al. (2012) Interleukin-1β: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology 37(4): 939–949. 10.1038/npp.2011.277
- Liu WL, Lin YH, Xiao H, Xing S, Chen H, Chi PD, et al. (2014) Epstein-Barr Virus infection induces indoleamine 2,3-dioxygenase expression in human monocyte-derived macrophages through p38/MAPK and NF-κB pathways: impairment in T cell functions. J Virol 88(12): 6660–6671. 10.1128/JVI.03678-13
- Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA (2000) Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 164(7): 3596–3599.
- Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune tolerance. Cell 133(5): 775–787. 10.1016/j.cell.2008.05.009
- Creelan BC, Antonia S, Bepler G, Garrett TJ, Simon GR, Soliman HH (2013) Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. OncoImmunology 2(3): e23428
- Song L, Rawal B, Nemeth JA, Haura EB (2011) JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther 10(3): 481–494. 10.1158/1535-7163.MCT-10-0502
- Lawrence S, Reid J, Whalen M (2013) Secretion of interferon gamma from human immune cells is altered by exposure to tributyltin and dibutyltin. Environ Toxicol 10.1002/tox.21932
- Schindler C, Levy DE, Decker T (2007) JAK-STAT signaling: from interferons to cytokines. J Biol Chem 282(28): 20059–20063.
- O'Shea JJ, Murray PJ (2008) Cytokine signaling modules in inflammatory responses. Immunity 28(4): 477–487. 10.1016/j.immuni.2008.03.002
- Russell MA, Cooper AC, Dhayal S, Morgan NG (2013) Differential effects of interleukin-13 and interleukin-6 on Jak/STAT signaling and cell viability in pancreatic β-cells. Islets 5(2): 95–105. 10.4161/isl.24249
- Orabona C, Pallotta MT, Volpi C, Fallarino F, Vacca C, Bianchi R, et al. (2008) SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci USA 105(52): 20828–20833. 10.1073/pnas.0810278105
- Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7(1): 41–51.
- Gariboldi MB, Ravizza R, Molteni R, Osella D, Gabano E, Monti E (2007) Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Lett 258(2): 181–188.
- Maleki Vareki S, Rytelewski M, Figueredo R, Chen D, Ferguson PJ, Vincent M, et al. (2014) Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin. Oncotarget 5(9): 2778–2791.
- Yoshida N, Ino K, Ishida Y, Kajiyama H, Yamamoto E, Shibata K, et al. (2008) Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model. Clin Cancer Res 14(22): 7251–7259. 10.1158/1078-0432.CCR-08-0991
- Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R (2011) Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res 17(22): 6985–6991. 10.1158/1078-0432.CCR-11-1331
- Iversen TZ, Engell-Noerregaard L, Ellebaek E, Andersen R, Larsen SK, Bjoern J, et al. (2014) Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin Cancer Res 20(1): 221–232. 10.1158/1078-0432.CCR-13-1560
Source: PubMed